Company intelligence / Profile preview

Gardia Medical

Ownership: Private
Development stage: Commercial

Overview

The WIRION Embolic Protection System demonstrated a major adverse event rate of only 1.9% in the WISE LE study—lower than previously reported rates for other embolic filters. No clinically significant distal embolization was observed when used. The device can be used with any .014” guidewire and all types of peripheral interventions; it’s the only embolic protection device indicated for use with any atherectomy system. Acquired by Cardiovascular Systems Inc. in August 2019; manufacturing transfer planned post-acquisition.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Drug pipeline

1 asset

WIRION

Commercial

Indications: Peripheral arterial disease, Carotid artery stenosis

Partnerships

Cardiovascular Systems Inc. acquired assets and commercial rights except for carotid artery applications

Beyond the preview

Go deeper on Gardia Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gardia Medical.

Explore the full profile